The TheraSphere Post-Approval Study is a post-market, prospective, single-arm,
open-label, observational study to support the use of TheraSphere for the treatment of
hepatocellular carcinoma (HCC).
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05233098.
Locations matching your search criteria
United States
Illinois
Chicago
Northwestern UniversityStatus: Active
Name Not Available
Every patient being treated with TheraSphere needs to have a screening procedure with the
administration of a radioactive product named Tc-99m MAA (called pre-treatment mapping).
This screening procedure aims to determine if the patient can be treated with
TheraSphere. The purpose of this study is to better understand the dose of radiation that
is absorbed by the body and the risk of Tc-99m MAA to the whole body and other organs
around the liver. The study will determine the amount of Tc-99m MAA that stays in the
body and organs up to 24 hours after the administration.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationBoston Scientific
